Volume 11, Number 6—June 2005
Research
Emergence and Spread of Streptococcus pneumoniae with erm(B) and mef(A) Resistance
David J. Farrell*
, Stephen G. Jenkins†, Steven D. Brown‡, Manish Patel§, Bruce S. Lavin§, and Keith P. Klugman¶#
, Stephen G. Jenkins†, Steven D. Brown‡, Manish Patel§, Bruce S. Lavin§, and Keith P. Klugman¶#Table 4
Susceptibility to various antibacterial drugs among Streptococcus pneumoniae isolates collected from years 1–3 of the PROTEKT US study that had both erm(B) and mef(A) macrolide resistance genes (n = 1,159)
| Drug | % susceptibility* | ||
|---|---|---|---|
| Susceptible | Intermediate | Resistant | |
| Amoxicillin–clavulanate† | 40.6 | 22.0 | 37.4 |
| Azithromycin | 0 | 0.1 | 99.9 |
| Cefuroxime | 5.7 | 1.7 | 92.6 |
| Clarithromycin | 0 | 0 | 100 |
| Co-trimoxazole | 3.4 | 1.2 | 95.4 |
| Erythromycin | 0 | 0 | 100 |
| Levofloxacin | 98.6 | 0 | 1.4 |
| Linezolid | 99.8 | 0 | 0.2 |
| Penicillin | 1.5 | 6.7 | 91.8 |
| Telithromycin | 99.0 | 0.9 | 0.1 |
| Tetracycline | 2.7 | 0.7 | 96.6 |
*Susceptibility was defined according to Clinical and Laboratory Standards Institute interpretive criteria (25).
†Amoxicillin alone was not tested; however, susceptibility can be extrapolated from the amoxicillin-clavulanate results.
